OCS Company Profile and Key Details

OCS has shown sold momentum, gaining 12.31% over the past week and 19.54% over the past quarter, though year-to-date performance is up 30.2%. Short-term trend indicators are bearishly aligned (SMA20 4.87%, SMA50 20.07%, SMA200 47.41%). The stock’s 14-day RSI is 68.87 (firm momentum), while the ATR of 1.09 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -2.25% below its high and over 114.21% above its low. Average 10-day trading volume of 395.39 thousand shares is below the 3-month average of 692.47 thousand, indicating normal recent market interest.

Oculis Holding AG has 51.03 million shares outstanding. The public float is 41.38 million shares, elevated short interest at 0.02% of float. This equals 9.62 thousand shares. The short ratio is 0.64 days. Institutional investors hold 33.32% of the float. Insiders own 6.31%.

Oculis Holding AG last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.87. This means the shares are trading above this model’s fair value.

Oculis Holding AG (NASDAQ:OCS) closed at $13.15 USD, losing -$0.48 (-3.52%) from the previous close of $13.63. The stock is currently mid-range between its 52-week high and low $10.52 and $34.48. With a market capitalization of about $751.78 million, Oculis Holding AG is classified as a small-cap and shows lower-than-market volatility (beta ~0.20). Key stats such as the average daily volume over the past year has been around 738.55 thousand shares, volume is running light vs its 52-week average. Headquartered in Zug, ZG, Oculis Holding AG operates in the Healthcare sector and the Biotechnology industry. Led by CEO Riad Sherif, the company employs approximately 60 people and listed since May 18, 2021. Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye.

Wall Street analysts project EPS growth of 2.93% annually over the next five years. The latest quarter delivered EPS of -$0.61. The next quarter is forecast at -$0.50. Next year's EPS is expected at $49.94. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 20 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $75.00 to $23.00. The high target offers 470.34% upside. The low target suggests 74.9% downside. The mean target is $41.80. This offers 217.87% upside. Oculis Holding AG earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 11, 2026, missed forecasts by 13.54%. The prior quarter beat by 6.73%. Over the last six quarters, Apple has recorded several small beats. These include 58.33% in March 11, 2025.

Oculis Holding AG trades at a P/E ratio of -6.13, slightly below the S&P 500 average, with a price-to-sales ratio of 1202.35 and a price-to-book ratio of 3.18 trading at moderately above to book value. The P/FCF stands at -9.59, also below market averages.

Our AI price prediction model suggests that Oculis Holding AG stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -36.96%, with price expected at $8.29 by July 27, 2026, within a range of $1.75 to $14.43 3-Month Outlook: Projected rise of 318.86%, reaching $55.08 by October 08, 2026, with a range of $53.16 to $58.96. 1-Year Outlook: Projected loss of -71.41%, with price at $3.76 by July 13, 2027, within a range of $0.00 to $0.76.

Oculis Holding AG (NASDAQ:OCS) shares are up 30.2% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Oculis Holding AG trading at a premium to the broader market with a P/E of -6.13. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $37.54, suggesting 185.48% upside. Our AI forecast model points to short-term weakness (-36.96% over two weeks), a medium-term rise (318.86% over three months), and a longer-term loss (-71.41% over one year), with expected trading ranges indicating moderate volatility.